Scott Wolchko | President and Chief Executive Officer |
Wayne Chu | Senior Vice President, Clinical development |
Ed Dulac | Chief Financial Officer |
Bob Valamehr | Chief Research and Development Officer |
Robyn Karnauskas | Truist Securities |
Ted Tenthoff | Piper Sandler |
Alethia Young | Cantor |
Yigal Nochomovitz | Citi |
Michael Yee | Jefferies |
Peter Lawson | Barclays |
Tazeen Ahmad | Bank of America |
Kelsey Goodwin | Guggenheim |
Daina Graybosch | SVB |
Mara Goldstein | Mizuho |
Nick Abbott | Wells Fargo |
Good day, ladies and gentlemen and welcome to the Fate Therapeutics First Quarter 2021 Financial Results Conference Call. This call is being webcast live on the Investors section of Fate Therapeutics website at fatetherapeutics.com. [Operator Instructions] I will now turn the call over to Scott Wolchko, President and CEO of Fate Therapeutics. Scott, you may begin.
Thank you.